Structural characterization of Posaconazole- parechovirus A3 capsid interaction using molecular simulations and cell infection assays
Parechovirus-A3 (PeV-A3) is a major cause of central nervous system infections in neonates, associated with meningoencephalitis and neurodevelopmental delays. Yet there are no specific antivirals against PeV-A3 infection. A newer clade of PeV-A3 has emerged post COVID-19, and our preliminary data shows that infants are not immune to the emerging variants, underscoring the need for a focused therapeutic discovery. Posaconazole (POS) is seen to attenuate PeV-A3 entry and infection, but the mechanistic understanding of drug-capsid interaction remains unknown. To this end, we combined mechanistic interrogation of drug-capsid interactions and conformational dynamics, with experimental infection assays. We identify two POS binding sites: a VP0-VP1 interface in the 2009 isolate (US WI-09), and a VP3-VP1 groove in the 2022 isolate (9C-CMKC) and a laboratory-selected POS-resistant variant (US WI-09 POSA P14). Apo simulations showed congruent trajectories of POS: to the VP0 face in US WI-09, and to the VP3 arm in 9C-CMKC and US WI-09 POSA P14. The relative contribution of VP0 to the drug-capsid interaction decreased from 86% in US WI-09 to zero in both 9C-CMKC and US WI-09 POSA P14, indicating a redistribution of binding interactions across capsid subunits. Cysteine or arginine substitutions to VP1 Tyr224 abolished the Tyr224-VP3 anchor. Functionally, 0.3 µM POS inhibited replication of US WI-09 and 9C-CMKC in Vero-P cells but only US WI-09 in receptor-overexpressing Vero-MYADM cells. These findings suggest that POS efficacy depends on binding-site localization near the MYADM-engaging VP0 interface, revealing how emerging PeV-A3 variants may retain drug binding while evading antiviral inhibition.
Authors
- Rahil Salehi
- Rangaraj Selvarangan (ORCID: https://orcid.org/0000-0003-3275-6657)
- Debarpan Dhar (ORCID: https://orcid.org/0000-0002-6776-5089)
- Ratul Chowdhury (ORCID: https://orcid.org/0000-0003-4522-6911)
Institutions
- Iowa State University (US)
- Children’s Mercy Research Institute (US)
- Mercy Research (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.11.765989
- Primary Topic
- Viral Infections and Immunology Research
- Type
- preprint
Funders
- National Science Foundation
- Centers for Disease Control and Prevention
- University of North Carolina at Chapel Hill
- Office of Experimental Program to Stimulate Competitive Research